NDA 021968 · Cppi Cv
Sutent
Sunitinib Malate · Oral
Accelerated approvalPriority reviewLast checked: Nov 19, 2026Latest source record: Feb 2, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jan 26, 2006
Approved uses
5
Original approval plus efficacy supplements
Registered trials
500
58 Phase 3, 25 recruiting
FAERS reports
39,149
30,215 serious, 11,688 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 2, 2007 Supplement 4 · Efficacy LabelLetterReview
- Feb 2, 2007 Supplement 5 · Efficacy · priority review LabelReviewLetter
- Feb 2, 2007 Supplement 3 · Efficacy ReviewLabelLetter
- Feb 2, 2007 Supplement 6 · Efficacy · priority review LabelReviewLetter
- Jan 26, 2006 Original approval · Type 6 - New Indication (no longer used) · priority review Accelerated approvalLabelReviewLetter
3 products under this application
- SUTENT · SUNITINIB MALATE EQ 50MG BASE · CAPSULE, ORAL · Prescription
- SUTENT · SUNITINIB MALATE EQ 12.5MG BASE · CAPSULE, ORAL · Prescription
- SUTENT · SUNITINIB MALATE EQ 25MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sunitinib Malate" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By SurgeryPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00326898 · 1,943 participants · Start Apr 24, 2006 · Primary completion Aug 27, 2015
Drug: Sorafenib Tosylate; Sunitinib Malate · For: Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer AJCC v6 and v7; Stage II Renal Cell Cancer AJCC v7 and 1 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 987 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Pan Tumor Rollover StudyRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03899155 · 1,500 participants (planned) · Start Aug 9, 2019 · Primary completion Aug 25, 2029
Drug: Nivolumab; Ipilimumab and 17 more · For: Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Lynwood, California · 410 sites in all
- Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell CarcinomaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00720941 · 1,110 participants · Start Aug 14, 2008 · Primary completion May 21, 2012
Drug: Pazopanib; Sunitinib · For: Carcinoma, Renal Cell
Sites: Huntsville, Alabama; Tucson, Arizona; Little Rock, Arkansas · 227 sites in all
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)Pivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02231749 · 1,096 participants · Start Oct 16, 2014 · Primary completion Jun 26, 2017
Drug: Nivolumab; Ipilimumab and 1 more · For: Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Sites: Duarte, California; La Jolla, California; Los Angeles, California · 189 sites in all
- Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver CancerPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT00699374 · 1,075 participants · Start Jul 2008 · Primary completion Dec 2011
Drug: sunitinib malate; sorafenib · For: Carcinoma, Hepatocellular
Sites: Fountain Valley, California; La Jolla, California; Orange, California · 171 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death7,452
- diarrhoea4,422
- fatigue4,195
- disease progression3,912
- nausea3,121
- asthenia2,461
- decreased appetite2,316
- vomiting2,211
- neoplasm progression2,020
- hypertension1,805
- dysgeusia1,696
- weight decreased1,589
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 777 |
| 2007 | 810 |
| 2008 | 838 |
| 2009 | 1,585 |
| 2010 | 3,423 |
| 2011 | 2,736 |
| 2012 | 3,177 |
| 2013 | 2,701 |
| 2014 | 3,143 |
| 2015 | 3,905 |
| 2016 | 3,384 |
| 2017 | 2,986 |
| 2018 | 2,531 |
| 2019 | 2,041 |
| 2020 | 1,594 |
| 2021 | 1,172 |
| 2022 | 1,066 |
| 2023 | 508 |
| 2024 | 314 |
| 2025 | 269 |
| 2026 | 188 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sutent (Sunitinib Malate)
2024 spending
$4.6M
Beneficiaries
78
364 claims
Per beneficiary
$59,222
$514.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $120,222,574 |
| 2021 | $96,954,410 |
| 2022 | $17,597,961 |
| 2023 | $7,397,129 |
| 2024 | $4,619,328 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E, Dahan L, Raoul JL, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Multicenter Study
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, et al. · N Engl J Med 2007 · Clinical Trial, Phase III, Comparative Study
- Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
Grillo F, Florio T, Ferraù F, et al. · Endocr Relat Cancer 2018 · Systematic Review
- Osteonecrosis of the jaws produced by sunitinib: a systematic review.
Vallina C, Ramírez L, Torres J, et al. · Med Oral Patol Oral Cir Bucal 2019 · Systematic Review
- Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.
Shanafelt T, Zent C, Byrd J, et al. · Leuk Lymphoma 2010 · Clinical Trial, Phase II, Multicenter Study
- Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R, Varley-Campbell J, Tikhonova I, et al. · Health Technol Assess 2018 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Cppi Cv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.